# ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

> **NCT05245760** · PHASE2 · WITHDRAWN · sponsor: **Zhonglin Hao**

## Conditions studied

- Esophageal Cancer
- Esophagogastric Junction Cancer

## Interventions

- **DRUG:** Intravenous Tislelizumab
- **DRUG:** Chemotherapy
- **RADIATION:** Fractionated radiation
- **PROCEDURE:** Esophagectomy

## Key facts

- **NCT ID:** NCT05245760
- **Lead sponsor:** Zhonglin Hao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04
- **Primary completion:** 2023-03
- **Final completion:** 2033-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding unavailable.
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245760, "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05245760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*